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Abstract
Background: Over recent years there has been a growth in cancer early diagnosis (ED) research, which requires valid
measurement of routes to diagnosis and diagnostic intervals. The Aarhus Statement, published in 2012, provided
methodological guidance to generate valid data on these key pre-diagnostic measures. However, there is still a wide
variety of measuring instruments of varying quality in published research. In this paper we test comprehension of self-
completion ED questionnaire items, based on Aarhus Statement guidance, and seek input from patients, GPs and ED
researchers to refine these questions.
Methods: We used personal interviews and consensus approaches to generate draft ED questionnaire items, then a
combination of focus groups and telephone interviews to test comprehension and obtain feedback. A framework analysis
approach was used, to identify themes and potential refinements to the items.
Results: We found that many of the questionnaire items still prompted uncertainty in respondents, in both routes to
diagnosis and diagnostic interval measurement. Uncertainty was greatest in the context of multiple or vague symptoms,
and potentially ambiguous time-points (such as ‘date of referral’).
Conclusions: There are limits on the validity of self-completion questionnaire responses, and refinements to the wording
of questions may not be able to completely overcome these limitations. It’s important that ED researchers use the best
identifiable measuring instruments, but accommodate inevitable uncertainty in the interpretation of their results. Every
effort should be made to increase clarity of questions and responses, and use of two or more data sources should be
considered.
Background
In the UK poor survival from cancer is attributed largely
to late stage diagnosis; there is growing evidence that diag-
nostic intervals influence prognostic outcomes [1–3].
Describing, in a systematic and valid way, the contribution
of routes to diagnosis, and associated diagnostic intervals,
to survival difference between countries is a current prior-
ity for the international research community – an example
of this effort is the International Cancer Benchmarking
Partnership [4].
The lack of consensus on the definitions and methods
used in cancer diagnosis research led to the development
and publication of the Aarhus statement [5], which pro-
vides methodological guidance on recording and report-
ing of time-point measurement, with the intention of
promoting consistency in studies based on diagnostic in-
tervals [6]. It also provides recommended definitions of
the key time-points for diagnostic and treatment path-
ways - from date of first presentation through to diagno-
sis and treatment (see Fig. 1). For example, the ‘date of
first presentation’ is defined as ‘the time point at which,
given the presenting signs, symptoms, history and other
risk factors, it would be at least possible for the clinician
seeing the patient to have started investigation or referral
for possible important pathology, including cancer’.
However, to date little work has explored how ques-
tionnaire/survey items, based on the Aarhus Statement
might be interpreted by patients and their health care
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providers - and the extent to which responses are a true
reflection of the measured time-points [7, 8].
Accordingly, in this study we developed a series of sur-
vey items about time-points, intervals and routes to diag-
nosis, based on Aarhus Statement definitions, with the
aim of testing the items with patients with two common
cancers (colorectal and lung cancer), GPs and cancer diag-
nosis researchers (CDRs). The key elements of the diag-
nostic pathway we examined are shown in Table 1. As
described in the Aarhus Statement [5]; 1) there are mul-
tiple routes to diagnosis for cancer patients, including
presentation to a GP with symptoms, emergency admis-
sions and screening. Better understanding of the pattern
of diagnostic routes in a population can help in efforts to
improve patient pathways 2) the key symptom prompting
action and 3) date of first presentation are also vital, but
can be hard to define, particularly in the presence of long-
standing or multiple symptoms 4) the volume/extent of
pre-diagnostic activity is important, as it reflects the level
of burden on patients, costs and complexity of patient
pathways 5) date of referral helps define the primary care
interval, but can cause confusion; particularly if there is
lack of clarity over what the referral is for (eg investiga-
tions, specialist consultations etc), and 6) date of diagno-
sis, the end-point of the diagnostic pathway, can be
defined in various ways – and patients and health care
providers can differ in their perceptions of this date.
Methods
We firstly generated questionnaire/survey items derived
from Aarhus Statement definitions (see Table 1) – item
generation was undertaken through a series of personal
interviews with early cancer diagnosis researchers and cli-
nicians (followed by a group consensus process, and an
examination of wording in existing validated instruments
[1, 9], drawing particularly on questionnaires used in the
International Cancer Benchmarking Partnership ‘Module
4’ surveys) [4]., We sought items which related to 1)
routes to diagnosis: for example, did patients see a GP
first, go straight to an A&E department etc., 2) the symp-
tom(s) and associated characteristics which prompted
help-seeking activity and 3) key time-points and intervals,
such as date of first presentation and date of referral – we
prompted the researchers and clinicians to take account
of the complexity in defining some of these time-points.
We were particularly interested in items which had high
relevance to early diagnosis, avoided abstract terms and
jargon, provided sufficient clarifying details and included a
spectrum of response options; in general we favoured
open-ended over closed questions. We then used a com-
bination of focus groups and telephone interviews with
patients (with or without a cancer diagnosis), GPs and
cancer diagnosis researchers (CDRs), conducted in May
and June 2015 in Edinburgh, UK to respond to the draft
items. There were both ‘patient’ and ‘GP’ versions of the
items (only the patient questions are shown, but the word-
ing of the GP questions was very similar).
Recruitment
Cancer patients were recruited either through the Edin-
burgh Cancer Centre or their general practice. Cancer
Centre patients were identified by a clinician (nurse or
consultant) and invited by the study researcher to par-
ticipate in the study; assurance was required from the
treating clinician that the patient had the ability to par-
ticipate in focus group discussions and capacity to pro-
vide informed consent. Thirteen patients with colorectal
cancer and 12 with lung cancer, all diagnosed in the pre-
vious 9 months, were recruited; there were no age re-
strictions. Eighteen participants without cancer were
Fig. 1 Cancer diagnostic intervals used in developing the Aarhus Statement [19]
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Table 1 Diagnostic pathway elements, survey items generated from Aarhus Statement definitions, and participant responses
Element of diagnostic pathway Survey items generated Exemplar participant responses
Route to diagnosis (eg through visit to
GP, via accident and emergency etc)
Which of the following best describes the events
which led to your diagnosis of cancer?
• I had symptoms/I noticed a bodily change and
went to see a doctor (eg GP, family doctor)
• I had symptoms/I noticed a bodily change and
was taken to Accident and Emergency
• I was being investigated by my doctor(s) for
another problem during which time the cancer
was discovered
• I had a cancer screening test (eg as part of a
programme offered by a health professional)
interviewer: OK so you don’t think you would fit it
either of these?
‘well what he’s saying he went to A&E but he
wasn’t diagnosed there’
(colorectal patient)
‘there’s sometimes a bit of overlap, so I think for the
majority of people those four options are
appropriate. There are times when someone might
have symptoms, but then attend A&E’ (GP)
I suppose if you were to add, I was being
investigated or monitored by my doctor for
another problem during which the cancer was
discovered, then that covers it’ (CDR)
what are we talking about here? Are we trying to
satisfy the sociologists? That’s not the purpose. I
wouldn’t use anything like ‘bodily change’; I would
use words, proper language, like ‘something was
wrong with me’ (CDR)
The key symptom/health problem which
prompted action (eg visiting a doctor)
by patient
• Looking back to the events which led to your
diagnosis of cancer, what was the main health
problem or symptom that made you contact a
doctor?
• Can you recall any other symptoms or health
problems which you now believe were
associated with the cancer?
‘I think that’s a very difficult question, sometimes it’s
easy, mine was passing blood, other times it could
be, as you say, a subtle thing that you don’t realise’
(colorectal patient)
‘So for alarm symptoms, I think it’s easier. But we
know that most cancers don’t actually present with
alarms symptoms, so I think for those cancers that
don’t present with an alarm symptom, then it…
then I think it is a bit more problematic’ (GP)
Date of first presentation to primary care • When did you first go to your general
practitioner with your symptoms of cancer?
• When did you first seek help for the symptoms
which you now believe were caused by your
cancer?
In response to a patient scenario: ‘I think I would
go for January 2008 on the grounds that the
cough was somehow kind of different and that the
cough had changed, so he might have had a kind
of smoker’s cough before but it was different for
January 2008’ (lung patient)
‘one of the difficulties is….. where you’ve got
somebody with a chronic recurring problem going
on for years, you know, without cancer being, you
know, maybe at the very first presentation cancer
being an issue, because of the cough or the
diarrhoea or abdominal pain, but then once it’s
excluded, you say, no, you’ve got irritable bowel
syndrome or, you know, you’ve got COPD and then
these patients come back time and time again and
then these two incidences that you’ve documented,
you know, they’re people with the same symptoms
for eight, 10 years….it’s the horrible difficulty that
we have in primary care saying, right, when is this
exacerbation of COPD or an exacerbation of
irritable bowel syndrome’ (GP)
Volume/extent of pre-diagnostic activity • How many times did you visit a GP/primary
care physician/family doctor and or hospital
about your symptoms before your cancer was
diagnosed?
• How many different doctors did you see in the
lead up to your diagnosis?
• How many different doctors/hospital
departments did you visit in the lead up to your
cancer diagnosis?
‘it probably also depends on the complexity of their
investigation. Some will be going quite easily
through a fast track pathway and others they
will…and of course it’s those patients that we
want to be able to make a distinction between.
Would it be easier to have boxes they can tick off,
two, four, six?’ (CDR)
‘It’s a very fluid thing actually, so a lot of the…and
a lot of stuff happens to…at the same time and in
different…I find that really difficult to make a clear
distinction between one and the other’ (GP)
‘maybe you need to say how many times you’ve
been to the GP, how many times, how many
hospital visits did you have before the cancer
diagnosis, separate into two questions
(colorectal patient)
Date of referral • When did your GP refer you to a specialist to
investigate you for symptoms of cancer?
‘the GP may refer somebody for investigation it
might be a x-ray or a CT scan but if you were
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recruited from two general practices in Edinburgh (one
each in areas of high and low deprivation). GPs and
CDRs were identified based on existing UK and inter-
national professional networks and contacted via email
to participate in the study. GPs (n = 4, 3 M, 1F) were
based in Scotland and associated with university depart-
ments of general practice. Cancer diagnosis researchers
(n = 6, 5F, 1 M) were based in Scotland, England,
Australia, Canada and Denmark; they were identified
through existing UK and international cancer research
networks; their disciplinary expertise included general
practice, epidemiology, social science and psychology -
all had at least 10 years of experience in early cancer
diagnosis research.
Focus groups – patient participants
The focus groups were semi-structured, and conducted
separately for colorectal, lung and non-cancer patients
by the study researcher (DC). They took place either at
the Edinburgh Cancer Centre or the participants’ general
Table 1 Diagnostic pathway elements, survey items generated from Aarhus Statement definitions, and participant responses
(Continued)
Element of diagnostic pathway Survey items generated Exemplar participant responses
• When would you say the responsibility for
further diagnosis and management of your
cancer transferred from your GP to specialist
cancer services?
saying referred to a specialist that comes after the
GP has got the results of the x-ray or the scan, so
in a sense there’s two things, there’s one referral for
investigation which might not come to anything
and then there’s referral to the specialist, so I think
we just need to be clear which one we’re looking
for’ (lung patient)
‘I just thought it was another process, the thing
that I was going through and I thought they all
worked together and my GP was there to guide me
to these people eh, but I could still go back and see
my GP whenever I wanted, do you know what I
mean, so it wasn’t like he cut off from, it was not
left to the specialist, you still have to visit your GP
and that, not as much obviously, but he was
always there to talk as well if I wanted’ (colorectal
patient)
‘it might go back to the definition of referral or
how it’s understood, because I suppose it seems
that your understanding is not that the
responsibility is gone forever and the patient has
been completely handed over because you’ll still be
involved in their care. Which is why I think the
word transferred we’ve used here is wrong’ (GP)
Date of diagnosis • When was your cancer diagnosed?
• What are you basing this date on? (eg date you
were told, date of operation, date of tests etc)
‘Yeah I mean it’s difficult because is somebody
saying to you I’m 90% sure that this is malignant,
it’s cancer, is that a confirmed diagnosis or was it
the next week when that same person rang me up
and he said ah we’ve had the result of the biopsy
and I was right, so from my point of view I would
say it was when he told me he was 90% sure,
because for me that’s a fairly strong indication’
(colorectal patient)
‘I would say for me as well the fact that it was the
consultant that did my colonoscopy, that was
when I found out that I had cancer, not when I
went to see the oncologist or the surgeon or
anything, they confirmed it obviously but it’s the, I
would say it’s the first person, I suppose like you
were saying the first person that mentions the c
word’ (colorectal patient)
‘You never forget the date, you remember the date
he told you you had cancer’ (lung patient)
‘are you meaning at what stage did the patient
understand the diagnosis, rather than when was
the GP told by the hospital, this patient has got X
wrong with him? They’re not simultaneous’
(non-cancer patient)
‘you could argue than when the bronchoscope
actually looks at the…eyeballs the tumour, they’re
able to say, you’ve got cancer, but I think most
people would wait for the histology’ (GP)
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practice. Participants were presented with the back-
ground and rationale for the study, and the Aarhus
Statement-derived survey items. Participants were asked
to identify, for each item, the potential challenges they
might face as patients in comprehending the item and
articulating responses. Participants were asked how ‘easy’
or ‘difficult’ they might find it to identify the key time-
points in their own pathway to diagnosis. The focus
group guide incorporated a series of probes based on the
cognitive model for survey response [10]. These probes
were:
 comprehension: what the respondent believed the
question to be asking, what specific words and
phrases meant to the respondent;
 recall: the type of information that the respondent
needed to recall in order to answer the question;
 judgment: whether the respondent devoted sufficient
mental effort to answer accurately and thoughtfully;
 response-mapping: whether the respondent matched
his or her internally generated answer to the
response categories given by the survey question
To further test comprehension, participants were pre-
sented with a hypothetical patient story involving a com-
plex patient pathway and asked for the dates which they
considered best reflected the time-point under consider-
ation. Participants were asked for further views about
the proposed approaches to establishing these time-
points in surveys of cancer patients.
Telephone interviews – GPs and CDRs
Interview documentation was sent to GPs and CDRs in
advance via email, and a convenient time arranged. The
telephone interviews were semi-structured; GPs were
asked for their views on their own challenges, and those
they anticipated their patients would face, in providing
responses to the survey items. CDRs were asked how
they felt patients and GPs would respond to the items –
and invited to comment on the likely validity of the sur-
vey item responses. Again, participants were presented
with a series of hypothetical patient stories to help eluci-
date issues in identifying time-points in complex diag-
nostic journeys. As with the patient interviews, the
interview schedule incorporated probes based on the
cognitive model for survey response [10].
All patient participants were offered £15 incentive
vouchers and compensation for their time and travel
expenses.
Data analysis
All focus groups and telephone interviews were audio-
recorded, transcribed verbatim and analysed using
framework analysis [11]; we chose this approach as it is
both pragmatic and iterative, with the capacity to re-
spond to themes as they emerge while maintaining a
clear link to the original transcripts. Two researchers
(DC and SS) developed an agreed framework involving a
‘double indexing’ approach - both researchers applied
the framework separately to one transcript from each
group. Once consensus in coding had been reached, DC
applied the framework to the remaining focus group
transcripts and indexed and charted the themes for each
survey item. To increase credibility, another two re-
searchers successfully applied the same framework to
two transcripts to gain consensus about its suitability
and applicability. During the mapping and interpretation
phase, implications for the development of the items
were considered by all members of the project team.
Ethical approvals
The study protocol was approved by the local research
ethics committee: South East Scotland (Ref: 13/SS/0221).
Results
Participant characteristics
Participant characteristics are summarised in Table 2.
Patients had a mixture of co-morbidities including arth-
ritis, carpel tunnel syndrome, hypertension, atrial fibril-
lation, heart disease, diabetes, osteoporosis, circulatory
and rheumatic problems. GPs (n = 4) were based in
Scotland; 3 were male. CDRs (n = 6) were based in
Scotland, England, Australia, Canada and Denmark; 5
were female. The survey items and the responses they
generated, guided by Aarhus Statement definitions are
shown in Table 1. We divided responses into the 6 previ-
ously described elements of the diagnostic pathway.
Route to diagnosis
Responses (shown in Table 1) reflect the complexity of
pre-diagnostic pathways, with many participants indicating
the 4 response categories didn’t cover all options – for ex-
ample if there had been a series of GP and A&E visits in
the lead up to the diagnosis. GP respondents also suggested
that there are overlaps between the potential pathways to
diagnosis and that some patients will have a combination of
two. CDRs queried whether the first pathways to diagnosis
options cover incidental discoveries (for example, a poten-
tial indicator of malignancy in a routine blood test) and






13 52–91 (67) M 10 F 3 4 employed, 6 not working
due to ill health, 3 retired
Lung cancer 12 43–89 (65) M 8 F 4 8 employed, 2 not working
due to ill health, 2 retired
Non-cancer 18 54–90 (75) M 12 F 6 12 employed, 6 retired
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whether a patient would think they’d been under ‘investiga-
tion’ by a doctor in this case. Both cancer and non-cancer
patients indicated they understood the difference between
screening and symptom-based (or incidental) cancer detec-
tion, but raised the issue that many subsequent questions
were not relevant to patients who have had their cancer de-
tected via screening programmes. GPs were less sure that
patients always understood the difference between screen-
ing and symptom-based diagnosis, particularly when inves-
tigations, such as a faecal occult blood test, could be used
as both a ‘screening’ and a ‘diagnostic’ test.
There were also concerns about terminology; the term
‘bodily change’ caused some confusion amongst partici-
pants, as many symptoms don’t produce changes in the
body such as lumps or weight loss. Others felt that
symptoms such as ‘rectal bleeding’ were, indeed, bodily
changes. CDRs suggested a greater use of lay language.
Main symptom/health problem which prompted action
There was consensus amongst almost all respondents
that symptoms can be difficult to recall – and may not
be thoroughly recorded in GP notes. Identifying a ‘main
symptom’ was considered to be potentially difficult, par-
ticularly in the context of multiple or vague symptoms.
Similarly, GPs found it easier to identify the main pre-
senting symptom when it was an ‘alarm symptom’, rather
than if the patient had multiple or vague symptoms.
Again there were issues around terminology; one CDR
thought the word ‘associated’ might invite respondents
to consider environmental or other causes of cancer.
Date of first presentation to primary care
As expected, participants differed in their understanding of
this date, particularly in the presence of vague, multiple,
intermittent or longstanding symptoms – there was no
consensus on how far in the past people should attempt to
recall symptoms. Many highlighted dates of consultations
prompted by changes in longstanding symptoms (for ex-
ample, when a cough became ‘hacking’ in nature). More-
over, in some cases there was a misattribution of symptoms
to an existing disease (eg irritable bowel syndrome or
COPD) making accurate identification of date of first pres-
entation difficult. GPs found recall for date of presentation
more difficult for patients who were frequent attenders, or
had chronic diseases – patients with ‘multiple morbidities’
posed a particular challenge, as consultations were often
complex, and symptoms of oncological significance could
be masked by other symptoms or priorities.
Volume/extent of pre-diagnostic activity
CDRs suggested that recall difficulty depends on com-
plexity of pathways; they suggested that patients will re-
member a few consultations at most. GPs suggested that
recall of extent and nature of activity is difficult, and the
distinction between activity in primary versus secondary
care can become blurred; they suggested listing the spe-
cialities of doctors seen (eg radiologist, GP, oncologist)
and the types of investigations undertaken (eg chest x
ray/CT scan/endoscopy/blood tests/fine needle aspir-
ation etc). Indeed, most respondents suggested this
question was ‘lumping a lot together’ and that it could
be separated out, specifying ‘hospitals departments’ and
‘doctors/specialties’.
Date of referral
This date was not always straightforward for respon-
dents. The greatest source of confusion arose over the
issue of what the referral was actually for – an investiga-
tion or a specialist consultation. Similarly cancer patients
queried the meaning of ‘referral’: we had suggested it
was the process by which ‘responsibility is transferred’
from their GP to a specialist, but many respondents in-
dicated the responsibility would continue to be shared
after the referral. GPs queried whether the term referral
means a ‘transfer of care from the GP’ since the GP will
continue to see and care for the patient thereafter.
Date of diagnosis
Patient participants mostly considered that ‘diagnosis’ con-
stitutes the date when the patient is first ‘told’ (often of a
suspicion by a consultant or by a GP). One respondent ar-
gued that the pathology report is the official final diagnosis
but the majority believed that pathology is a means of sta-
ging the extent of the cancer. Overall, though, cancer pa-
tients agreed that date of diagnosis (the date they were
told) is considered so significant it can be recalled easily
(particularly with the assistance of a diary) – so it is the date
they are most likely to report. Non-cancer patients also
emphasised that the clinical diagnosis (as perceived by a
health care provider) is not the same as the patients’ experi-
ence of the diagnosis – this likely contributes to differences
between doctor and patient reports of date of diagnosis.
Most GPs indicated that they take the date of confirmation
of histology as the date of diagnosis. It was suggested that
receipt of the consultant’s letter/date GP informed (even
though the GP may, at times, make the diagnosis) are also
important and so should be included in response options.
Discussion
Our study adds to a growing body of methodological lit-
erature on measurement of routes to a cancer diagnosis
and diagnostic time intervals; it demonstrates the many
challenges and pitfalls associated with their accurate
measurement. We based our survey items as closely as
possible on Aarhus Statement definitions, yet found that
enquiry often still prompted considerable uncertainty.
While there is growing interest in measuring cancer
diagnostic intervals, to examine their effect on cancer
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outcomes and to make international comparisons, we
currently lack standardised measuring instruments. The
challenges in measurement of routes to diagnosis arise
from the frequent complexity of cancer patients’ jour-
neys, the existence of co-morbid conditions, and the na-
ture of cancer symptoms, which are often multiple and
vague [6, 12, 13].
The importance of accurate measurement in ‘routes to
diagnosis’ research
Establishing patterns of routes to diagnosis is important
for health service planning – for example, there is current
interest in reducing emergency cancer presentations [14,
15]; measuring outcomes of any initiatives in this area re-
quires a clear distinction between a cancer diagnosed in
general practice compared to a cancer diagnosis arising
from a presentation to A&E. Our study demonstrates the
care needed in making this distinction, because these two
diagnostic paths can, in the presence of multiple presenta-
tions over a limited period of time, become blurred. Simi-
larly, while our patient respondents denied any confusion
over what constitutes a screening pathway (eg no symp-
toms, participation in an organised programme), other re-
search has demonstrated that confusion does, indeed,
often exist [4], and patients’ understanding of the route
they’ve taken needs careful interpretation.
Defining the ‘main symptom’ which prompted help-seek-
ing is important in early diagnosis research but, again, this
symptom may be elusive – and, it may be influenced by
pre-existing knowledge [6, 16]; or mis-attribution, particu-
larly in the presence of chronic illness or multiple symp-
toms [17].
The primary care interval (beginning with date of first
presentation and ending with date of referral) is also the
subject of international interest; in systems where pri-
mary care acts as the ‘gatekeeper’ to health services, it’s
important to ensure that symptoms are responded to in
a timely and appropriate way, and referrals made to ap-
propriate specialist cancer services. So we need accurate
measures of this interval but, particularly in the presence
of multiple or vague symptoms, which may be persistent
for long periods of time, ‘date of first presentation’ can
be difficult to specify. Even with the help of case records,
GPs may struggle to identify at which consultation the
‘first’ presentation of a symptom occurred. Similarly,
date of referral and date of diagnosis can cause confu-
sion if not sufficiently specified.
Study limitations and strengths
Our study confined its analysis to survey items which
might be used in self-completion surveys. There are
other methods for measuring diagnostic intervals and
routes to diagnosis; the interactive dialogue of an
interview-based survey would, for example, allow some
of the comprehension and clarity issues of time-point
recall to be resolved. But it is likely also that self-com-
pletion questionnaires will remain a feature of ‘routes
to diagnosis’ cancer research, as they enable large sam-
ple sizes - so it is important to understand the cognitive
processes respondents utilise, and the challenges in
comprehension they face, when responding to written
questions.
Focus group discussions can lead to bias - for example,
participants may alter their view in order to fit into the
group or as an attempt to please the researcher/facilita-
tor (‘social desirability bias’) [18]. Nevertheless, the study
used an experienced qualitative researcher and employed
techniques to minimize this bias.
We’ve not formally tested the psychometric properties
of the items we’ve identified – however, in the next
phase of the study (reported separately) we undertake an
e-delphi consensus process in which we further examine,
for both patients and GPs, how understandable the
items are, and how feasible respondents consider the
items are to answer. Nevertheless, we acknowledge the
limitations of self-completion instruments, and the con-
straints on their capacity to capture some of the com-
plexity of cancer diagnostic journeys. We’ve purposefully
not produced, as part of this work, an ‘off-the-shelf ’ vali-
dated instrument which other CDRs might use. Rather,
we considered that the most useful output would be to
1) see the questions we tested, 2) hear from potential re-
cipients of ED questionnaires (principally patients and
GPs) about the potential value and limitations of the
questions, and 3) to produce a list of recommendations
which might guide future instrument development.
Finally, even though we obtained broad and diverse re-
sponses from our GPs and CDRs, the number of partici-
pants was small, which places some limitations on the data.
Recommendations
We recommend that self-completion-based surveys
either include extra clarifying text, or opportunities to
directly interact with participants, to address the follow-
ing issues:
 Route to diagnosis – researchers should
accommodate the uncertainty over emergency/A&E
presentations versus diagnoses via primary care
routes. There are scenarios (such as GP referral to
A&E) which can lead to lack of clarity, and
methodological guidance on this key issue is
emerging [15]. Steps should also be taken to reduce
ambiguity over what constitutes ‘screening’. While
health care providers can readily identify a screening
route to diagnosis, patients may not appreciate the
difference between a screening and diagnostic
examination – particularly, for example, if they had
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symptoms at the time of taking a screening test. There
are also international differences in the ways terms
such as ‘screening’ and ‘early diagnosis’ are interpreted
 Main symptom prompting action – there may not be
single symptom – and the symptom(s) may be vague
or intermittent. Indeed, one ‘main symptom’ may be
replaced by another.
 Date of first presentation – diagnostic journeys are
often non-linear, and a ‘true’ date of first presentation
may be hidden amongst other pre-diagnostic activity.
In some cases it may not be possible to identify a
single consultation representing ‘first presentation’ –
in which case a pragmatic but transparent approach
might be needed to identify a ‘date of best fit’.
 Extent of pre-diagnostic activity – in many cases this
can be too much to recall; ideally prompts should be
used to categorise this activity
 Date of referral – there should be clarity over what
the referral was for – the Aarhus statement
recommends transfer of care to specialist services,
rather than referral for diagnostic investigations [5]. In
gatekeeper systems we seek to define this date as it
represents the end of the primary care interval – but
caution is needed; as our patient and GP respondents
indicate, there isn’t necessarily a distinct time-point at
which care transfers from primary to secondary care.
There may be an ‘overlapping’ period of shared
responsibility.
 Date of diagnosis – our study illustrates differing
perceptions amongst patients and GPs, and these
need to be recognised when interpreting responses.
Patients appear to consistently view this date as the
time they were made aware of their diagnosis – this
may be substantially different to the date of
histological confirmation.
Conclusions
Measuring routes and time intervals in cancer diagnostic
pathways is a complex task. In the past there has been
little methodological rigour in studies reporting diagnos-
tic intervals. While the Aarhus Statement has helped to
standardise approaches, there are still significant chal-
lenges in developing methods of enquiry which elicit
valid responses. This study highlights many of the areas
where ED researchers need to be especially cautious in
measuring time-points and interpreting responses.
While the results of the study give an important steer on
questionnaire wording, it should be acknowledged that
measuring complex routes to diagnosis with self-com-
pletion questionnaires requires caution, and steps should
be taken to increase clarity of responses wherever pos-
sible. A further option is to use more than one data
source to enable ‘triangulation’ of responses – although
this will likely entail further cost and burden. Our rec-
ommendations are designed to complement those in the
Aarhus Statement, and should assist CDRs in developing
improved survey instruments – and in interpreting the
data those instruments generate.
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